Genetic Basis of Drug Response
The genetic basis of drug response is the study of how inherited differences in a person's DNA shape how they handle and react to medicines. Variation in genes that encode drug-metabolizing enzymes, transporters, and drug targets helps explain why the same dose of the same drug can be effective in one patient, ineffective in another, and toxic in a third. This area, historically called pharmacogenetics, provides the conceptual foundation on which pharmacogenomics and personalized prescribing are built.
Definition
The genetic basis of drug response refers to the inherited DNA variation - chiefly single-nucleotide polymorphisms, insertions, deletions, copy-number variants, and the haplotypes they form - that contributes to interindividual differences in drug absorption, distribution, metabolism, excretion, efficacy, and toxicity.
Scope
This area orients the reader to the heritable component of drug response: the major classes of pharmacogenes (metabolizing enzymes, transporters, targets, and immune-related loci), how genetic polymorphism translates into measurable differences in pharmacokinetics and pharmacodynamics, and how genotype is mapped to predicted phenotype. It frames these as reference concepts in medical genetics rather than as prescribing instructions, and points to the more detailed topics nested beneath it.
Sub-topics
Core questions
- Which genes and genetic variants influence how an individual processes and responds to a given drug?
- How does inherited variation translate from genotype into pharmacokinetic and pharmacodynamic phenotype?
- Why do drug efficacy and adverse-reaction risk differ between individuals and across populations?
- What proportion of variability in drug response is heritable versus environmental?
Key concepts
- Pharmacogene (drug-metabolizing enzyme, transporter, target, immune locus)
- Genetic polymorphism and haplotype
- Genotype-to-phenotype prediction
- Pharmacokinetic versus pharmacodynamic variation
- Heritability of drug response
- Population and ancestry differences in allele frequency
- Monogenic versus polygenic determinants of response
Mechanisms
Inherited variation affects drug response along two broad axes. Pharmacokinetic variation arises when polymorphisms in genes for metabolizing enzymes (such as the cytochrome P450 family) or membrane transporters change how much active drug reaches its site of action and for how long. Pharmacodynamic variation arises when variants in the drug's molecular target, or in downstream signalling and immune-recognition pathways, alter the magnitude of the biological effect at a given concentration. Both single high-impact variants (monogenic traits) and the combined small effects of many loci (polygenic traits) contribute, and the same functional consequence can result from different variants in the same gene.
Clinical relevance
Understanding the genetic basis of drug response is part of the rationale for pharmacogenomic testing and personalized prescribing, and it helps explain observed patterns of treatment failure and adverse drug reactions. As a reference area it describes how heritable variation is conceptualized and studied; it does not provide dosing rules or individualized treatment recommendations, which are the domain of validated clinical guidelines applied by qualified clinicians.
Epidemiology
Adverse drug reactions are a substantial cause of hospital admissions and inpatient morbidity, and a fraction of this burden is attributable to genetically influenced variation in drug handling and immune response. The frequencies of clinically relevant pharmacogenetic variants differ markedly between ancestral populations, which is why allele-frequency data and population genetics are integral to this field.
History
The field began with mid-twentieth-century observations that traits such as slow isoniazid acetylation and pseudocholinesterase deficiency ran in families and predicted unusual drug reactions, work synthesized under the term pharmacogenetics by Werner Kalow. With the completion of the Human Genome Project and the maturation of genotyping, the discipline broadened into pharmacogenomics, reframed by Evans and Relling as the translation of functional genomics into rational therapeutics, and later consolidated into clinical implementation efforts.
Key figures
- Richard Weinshilboum
- William Evans
- Mary Relling
- Howard McLeod
- Werner Kalow
Related topics
Seminal works
- weinshilboum-2003
- evans-1999
- wang-2011
Frequently asked questions
- What is the difference between pharmacogenetics and pharmacogenomics?
- Pharmacogenetics traditionally refers to the study of single genes (often one enzyme) and their effect on drug response, while pharmacogenomics describes the broader, genome-wide study of many genes and variants influencing how drugs work; the terms are now often used interchangeably.
- Does genetics fully determine how a person responds to a drug?
- No. Inherited variation is one important contributor, but age, organ function, other medications, disease, diet, and adherence also shape drug response, so genotype predicts tendencies rather than guaranteeing an outcome.